Apollo signs $500,000 deal with Symansis
11 June, 2008 by Dylan Bushell-EmblingIncludes the sale of assets and licensing of proprietary techniques
ChemGenex acquires leukaemia drug outright
11 June, 2008 by Dylan Bushell-EmblingLarge stock trade to take place of royalty payments
Court approves pSvida re-incorporation
11 June, 2008 by Dylan Bushell-EmblingRe-lists on NASDAQ, temporary halt on ASX
Director of Resmed board resigns
10 June, 2008 by Dylan Bushell-EmblingFarrell to continue as executive director
pSvida to list on Nasdaq
10 June, 2008 by Dylan Bushell-EmblingShareholders agree to re-incorporation on US stock exchange
Clinical Cell Culture renames
10 June, 2008 by Dylan Bushell-EmblingC3 changes name to Avita Medical
BIO 2008: Australia goes to BIO
06 June, 2008 by Staff WritersExhibitors on the Australian Pavilion at BIO 2008 in San Diego
BIO 2008: QTCN goes to BIO
06 June, 2008 by Staff WritersExhibitors on the QTCN booth at BIO 2008 in San Diego
Benitec in the clinic
06 June, 2008 by Dylan Bushell-EmblingEarly results from RNAi trial promising
BIO 2008: Waking up to sleeping sickness
06 June, 2008 by Matt RodgersWA company Epichem and the Drugs for Neglected Diseases initiative are collaborating to develop new drugs to treat African sleeping sickness and similar, forgotten diseases.
Stem cells for heart failure
06 June, 2008 by Dylan Bushell-EmblingMesoblast's sister company plans phase II trials for congestive heart failure
LCT expands diabetes trial
06 June, 2008 by Dylan Bushell-EmblingLCT has doubled both the sample size and dosage for next stage of clinical tria
Arana superhumanises CSL
06 June, 2008 by Dylan Bushell-EmblingArana Therapeutics completes research project with CSL
